Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

Clinical trial NCT05231369 · UNKNOWN

Trial details

NCT number: NCT05231369
Sponsor: Chulalongkorn University
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine Immune Response of 50 ug of ChulaCov19-BNA159 mRNA Vaccine Assess Which Dose is Appropriate to Use

Start date: 2022-12-14
Primary completion: 2023-07-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.